Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
47
AMRX Quote, Financials, Valuation and Earnings
Last price:
$7.78
Seasonality move
:
-4.53%
Day range:
$7.57 - $7.86
52-week range:
$5.01 - $9.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.86x
P/B ratio:
--
Volume:
1.7M
Avg. volume:
1.2M
1-year change:
47.07%
Market cap:
$2.4B
Revenue:
$2.4B
EPS (TTM):
-$0.68
Analysts' Opinion
-
Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Amneal Pharmaceuticals has an estimated upside of 34.96% from its current price of $7.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.78.
Fair Value
-
According to the consensus of 0 analysts, Amneal Pharmaceuticals has 34.96% upside to fair value with a price target of -- per share.
AMRX vs. S&P 500
-
Over the past 5 trading days, Amneal Pharmaceuticals has overperformed the S&P 500 by 1.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Amneal Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amneal Pharmaceuticals has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Amneal Pharmaceuticals reported revenues of $702.5M.
Earnings Growth
-
Amneal Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Amneal Pharmaceuticals reported earnings per share of -$0.00.
Enterprise value:
4.9B
EV / Invested capital:
1.97x
Price / LTM sales:
0.86x
EV / EBIT:
36.98x
EV / Revenue:
1.84x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
21.51x
Price / Operating cash flow:
10.02x
Enterprise value / EBITDA:
13.68x
Gross Profit (TTM):
$947.4M
Return On Assets:
-5.24%
Net Income Margin (TTM):
-6.88%
Return On Equity:
-587.3%
Return On Invested Capital:
-6.95%
Operating Margin:
10.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1B | $2.4B | $2.7B | $620M | $702.5M | |
| Gross Profit | $735.7M | $846.1M | $947.4M | $232.5M | $269.6M | |
| Operating Income | $133.7M | $259.5M | $278.8M | $76.5M | $76.5M | |
| EBITDA | $128.8M | $467.2M | $360.3M | $131.1M | $139.9M | |
| Diluted EPS | -$0.87 | $0.06 | -$0.68 | $0.06 | -$0.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5B | $1.6B | $1.4B | $1.5B | $1.5B | |
| Total Assets | $4B | $4B | $3.9B | $3.7B | $3.5B | |
| Current Liabilities | $667.9M | $667.3M | $818M | $760.6M | $1.1B | |
| Total Liabilities | $3.7B | $3.6B | $3.7B | $3.5B | $3.5B | |
| Total Equity | $348.2M | $383.2M | $216.7M | $191.4M | -$33.7M | |
| Total Debt | $2.8B | $2.8B | $2.7B | $2.7B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $151.7M | $186.5M | $312.8M | $81.4M | $141.8M | |
| Cash From Investing | -$249.8M | -$49M | -$78.6M | -$13.5M | -$20.7M | |
| Cash From Financing | -$114.8M | -$133.9M | -$251.4M | -$86.6M | -$92.3M | |
| Free Cash Flow | $53.3M | $137.5M | $229.2M | $67.9M | $121.1M | |
AMRX
Sector
Market Cap
$2.4B
$43.9M
Price % of 52-Week High
82.11%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
47.07%
-29.11%
Beta (5-Year)
1.122
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.86
200-day SMA
Buy
Level
$7.37
Bollinger Bands (100)
Sell
Level
7.85 - 8.79
Chaikin Money Flow
Sell
Level
-8.1M
20-day SMA
Sell
Level
$8.19
Relative Strength Index (RSI14)
Sell
Level
39.52
ADX Line
Sell
Level
1.95
Williams %R
Buy
Level
-84.2105
50-day SMA
Sell
Level
$8.42
MACD (12, 26)
Sell
Level
-0.20
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-19.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1605)
Sell
CA Score
(Annual)
Level (-2.0904)
Buy
Beneish M-Score
(Annual)
Level (-3.1805)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.2142)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Stock Forecast FAQ
In the current month, AMRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AMRX average analyst price target in the past 3 months is --.
-
Where Will Amneal Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amneal Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Amneal Pharmaceuticals?
Analysts are divided on their view about Amneal Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amneal Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Amneal Pharmaceuticals's Price Target?
The price target for Amneal Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AMRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amneal Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AMRX?
You can purchase shares of Amneal Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amneal Pharmaceuticals shares.
-
What Is The Amneal Pharmaceuticals Share Price Today?
Amneal Pharmaceuticals was last trading at $7.78 per share. This represents the most recent stock quote for Amneal Pharmaceuticals. Yesterday, Amneal Pharmaceuticals closed at $7.78 per share.
-
How To Buy Amneal Pharmaceuticals Stock Online?
In order to purchase Amneal Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 1.36% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.63% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.53% over the past day.
